menu
    • menu
    [{"orgOrder":0,"company":"Yale University","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Elotuzumab","moa":"SLAM family member 7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Yale University \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"Yale University \/ GSK"},{"orgOrder":0,"company":"Omar Nadeem, MD","sponsor":"Bristol Myers Squibb | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Elotuzumab","moa":"SLAM family member 7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omar Nadeem, MD","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omar Nadeem, MD \/ Bristol Myers Squibb | Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Omar Nadeem, MD \/ Bristol Myers Squibb | Bristol Myers Squibb"},{"orgOrder":0,"company":"Natalie Callendar","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Elotuzumab","moa":"SLAM family member 7","graph1":"Oncology","graph2":"Phase II","graph3":"Natalie Callendar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Natalie Callendar \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Natalie Callendar \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Autoimmunity Centers of Excellence | Bristol Myers Squibb | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Elotuzumab","moa":"SLAM family member 7","graph1":"Immunology","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Autoimmunity Centers of Excellence | Bristol Myers Squibb | Rho, Inc","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Autoimmunity Centers of Excellence | Bristol Myers Squibb | Rho, Inc"},{"orgOrder":0,"company":"Tulane University School of Medicine","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Elotuzumab","moa":"SLAM family member 7","graph1":"Oncology","graph2":"Phase II","graph3":"Tulane University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tulane University School of Medicine \/ Karyopharm Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Tulane University School of Medicine \/ Karyopharm Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals for Elotuzumab

    Menu

    Elotuzumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Omar Nadeem, MD

                            Country arrow
                            Coatings Trends
                            Not Confirmed

                            Omar Nadeem, MD

                            Country arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elotuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Bristol Myers Squibb | Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            July 24, 2024

                            Lead Product(s) : Elotuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Bristol Myers Squibb | Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tulane University School of Medicine

                            Country arrow
                            Coatings Trends
                            Not Confirmed

                            Tulane University School of Medicine

                            Country arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elotuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Karyopharm Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            December 28, 2021

                            Lead Product(s) : Elotuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Karyopharm Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Yale University

                            Country arrow
                            Coatings Trends
                            Not Confirmed

                            Yale University

                            Country arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elotuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : GSK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            August 12, 2021

                            Lead Product(s) : Elotuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : GSK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            National Institute of Allergy and Infectious Diseases

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            National Institute of Allergy and Infectious Diseases

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elotuzumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Autoimmunity Centers of Excellence | Bristol Myers Squibb | Rho, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            June 08, 2021

                            Lead Product(s) : Elotuzumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Autoimmunity Centers of Excellence | Bristol Myers Squibb | Rho, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Natalie Callendar

                            Country arrow
                            Coatings Trends
                            Not Confirmed

                            Natalie Callendar

                            Country arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elotuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            October 12, 2020

                            Lead Product(s) : Elotuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Wuerzburg University Hospital

                            Country arrow
                            Coatings Trends
                            Not Confirmed

                            Wuerzburg University Hospital

                            Country arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elotuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : ClinAssess | Arbeitsgemeinschaft medikamentöse Tumortherapie

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            May 13, 2019

                            Lead Product(s) : Elotuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : ClinAssess | Arbeitsgemeinschaft medikamentöse Tumortherapie

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Moffitt Cancer Center

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            Moffitt Cancer Center

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elotuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            January 25, 2018

                            Lead Product(s) : Elotuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Wake Forest University Health Sciences

                            Country arrow
                            Coatings Trends
                            Not Confirmed

                            Wake Forest University Health Sciences

                            Country arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elotuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Bristol Myers Squibb | Atrium Health Levine Cancer Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            December 04, 2017

                            Lead Product(s) : Elotuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Bristol Myers Squibb | Atrium Health Levine Cancer Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elotuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in ...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            July 24, 2017

                            Lead Product(s) : Elotuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Bristol Myers Squibb

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            Bristol Myers Squibb

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elotuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            April 24, 2017

                            Lead Product(s) : Elotuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth